Wall Street analyst estimates for Precision BioSciences, Inc. (DTIL): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 12 |
| Avg rating (1-5) | 0.75 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-02 | $-0.85 | ||
| 2026-08-06 | $-1.26 | $-0.80 | -56.7% |
| 2026-05-05 | $-0.75 | $-0.27 | -177.8% |
| 2026-03-12 | $1.05 | $-0.21 | +600.0% |
| 2025-11-03 | $-1.84 | $-0.31 | -493.5% |
| 2025-08-07 | $-2.13 | $-0.09 | -2266.7% |
| 2025-05-15 | $-2.21 | $-0.43 | -414.0% |
| 2025-03-26 | $-3.20 | $-2.09 | -53.1% |
Valuation Ratios
| Price / Book | 3.78 |
| EV / EBITDA | -0.76 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0M | $6.5M | $10.9M | $22.2M | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | $7.0M | $6.5M | $10.9M | $22.2M | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| Research & Development | $9.1M | $20.3M | $45.1M | $82.4M | $98.1M | $115.2M | $46.1M | $53.4M | $59.6M | $54.2M |
| Selling, General & Admin | $6.1M | $8.0M | $13.7M | $27.0M | $36.1M | $39.7M | $41.3M | $39.1M | $35.3M | $32.2M |
| Operating Expenses | $15.2M | $28.3M | $58.8M | $109.4M | $134.1M | $154.9M | $87.4M | $92.5M | $94.9M | $86.4M |
| Operating Income | -$8.8M | -$22.0M | -$47.9M | -$87.2M | -$109.8M | -$39.4M | -$62.3M | -$43.7M | -$26.2M | -$52.1M |
| EBITDA | -$8.2M | -$20.4M | -$43.7M | -$87.4M | -$99.2M | -$20.3M | -$62.8M | -$32.0M | $13.5M | -$42.4M |
| Interest Expense | 0 | 0 | 0 | $182000 | 0 | $132000 | $1.1M | $2.2M | $1.8M | $1.4M |
| Pre-tax Income | -$8.3M | -$21.1M | -$46.0M | -$92.9M | -$109.0M | -$30.6M | -$72.9M | -$42.5M | $7.2M | -$46.6M |
| Income Tax | -$5000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$8.3M | -$21.1M | -$46.0M | -$92.9M | -$109.0M | -$30.6M | -$111.6M | -$61.3M | $7.2M | -$45.7M |
| EPS | $-0.49 | $-18.81 | $-28.17 | $-59.50 | $-62.85 | $-15.60 | $-38.10 | $-15.96 | $1.05 | $-3.56 |
| EPS (Diluted) | $-0.49 | $-18.81 | $-28.17 | $-59.50 | $-62.85 | $-15.60 | $-38.10 | $-15.96 | $1.04 | $-3.56 |
| Shares Outstanding (Diluted) | $16.7M | $1.1M | $1.6M | $1.4M | $1.7M | $2.0M | $2.9M | $3.8M | $6.9M | $12.8M |
Price
| Price | $6.63 |
| Market Cap | $85M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABOS · ALEC · GOSS · HOOK · HRTX · KLDO · QTTB
Explore sector: Healthcare · Biotechnology
More sections of DTIL: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks